Details
Stereochemistry | RACEMIC |
Molecular Formula | C14H17NO2 |
Molecular Weight | 231.2903 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(OC1CN2CCC1CC2)C3=CC=CC=C3
InChI
InChIKey=AHKAOMZZTQULDS-UHFFFAOYSA-N
InChI=1S/C14H17NO2/c16-14(12-4-2-1-3-5-12)17-13-10-15-8-6-11(13)7-9-15/h1-5,11,13H,6-10H2
Molecular Formula | C14H17NO2 |
Molecular Weight | 231.2903 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Benzoclidine (Oxylidin) exerts tranquilizing and hypotensive actions. It reduces the excitability of the central nervous system, enhances the effect of hypnotic drugs, analgesics and local anesthetics, has a moderate antihypertensive effect, reduces the excitability of the vasomotor centers, has anti-arrhythmic activity. Benzoclidine is marke indicated for the treatment of anxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0050877 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Benzoclidine Approved UseAnxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia. |
|||
Primary | Benzoclidine Approved UseAnxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia. |
|||
Primary | Benzoclidine Approved UseAnxiety and depression of various origins (particularly mild expressed and associated with cerebrovascular insufficiency), neurosis, personality disorder, cyclothymia, hypertension with cerebral disorders, sinus tachycardia, paroxysmal tachycardia. |
PubMed
Title | Date | PubMed |
---|---|---|
[ON THE RELATIONSHIP BETWEEN THE HYPOTENSIVE EFFECT OF OXYLIDIN AND ITS EFFECT ON CENTERS OF THE MEDULLA OBLONGATA AND CARDIAC ACTIVITY]. | 1964 Jan-Feb |
|
[OXYLIDIN THERAPY OF PATIENTS WITH CEREBROVASCULAR DISEASES WITH MENTAL DISORDERS]. | 1965 |
|
[CLINICAL TESTING OF OXYLIDIN, A NEW HYPOTENSIVE AGENT, IN THE TREATMENT OF HYPERTENSION]. | 1965 Feb |
|
[Experience in the treatment of hypertensive patients with oxylidin under polyclinical conditions]. | 1965 Nov |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:00:10 GMT 2023
by
admin
on
Fri Dec 15 16:00:10 GMT 2023
|
Record UNII |
G84189YY06
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29756
Created by
admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000086387
Created by
admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
|
PRIMARY | |||
|
66-93-3
Created by
admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
|
SUPERSEDED | |||
|
3086
Created by
admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
|
PRIMARY | |||
|
CHEMBL121932
Created by
admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
|
PRIMARY | |||
|
760346
Created by
admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
|
PRIMARY | |||
|
G84189YY06
Created by
admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
|
PRIMARY | |||
|
C77243
Created by
admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
|
PRIMARY | |||
|
65630
Created by
admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
|
PRIMARY | |||
|
m9469
Created by
admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB05756MIG
Created by
admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
|
PRIMARY | |||
|
16852-81-6
Created by
admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
|
PRIMARY | |||
|
DTXSID0046191
Created by
admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
|
PRIMARY | |||
|
C000662
Created by
admin on Fri Dec 15 16:00:10 GMT 2023 , Edited by admin on Fri Dec 15 16:00:10 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |